Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Why AvenCell Therapeutics is using AVC-203 to test whether allogeneic CAR-T can move beyond manufacturing bottlenecks
AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.